Scientists develop antibody-ligand traps for checkpoint inhibitor-resistant cancers

A study showed a bifunctional antibody-ligand trap compound comprised of a checkpoint inhibitor and an ectodomain sequence from transforming growth factor (TGF)

Read the full 228 word article

User Sign In